Stem Cell Therapeutics Corp.
TSX VENTURE : SSS

Stem Cell Therapeutics Corp.

October 20, 2008 11:43 ET

Stem Cell Therapeutics Corp. Invited to Present at Florida's Largest Bioscience Forum

CALGARY, ALBERTA--(Marketwire - Oct. 20, 2008) - Stem Cell Therapeutics Corp. ("SCT") (TSX VENTURE:SSS) announces today Dr. Alan Moore, President and CEO, will be participating in a panel discussion at BioFlorida's 11th Annual Conference to be held October 19-21 at the Ritz-Carlton in Amelia Island, Florida. The panel discussion, titled "Individualized Medicine", will be chaired by Dr. Todd E. Golde, Professor and Consultant in the Department of Neuroscience at the Mayo Clinic Jacksonville. In addition to Dr. Moore, the panel includes Dr. Daniel Kelly, Scientific Director and Professor at the Burnham Institute for Medical Research and Dr. Dennis Steindler, Professor of Neuroscience and Neurosurgery at the University of Florida, College of Medicine.

The panel discussion will highlight how discovery science is leading to individualized and personal medicine, specifically in relation to stem cell based therapies, and what the potential for translation into the commercial sector. Dr. Alan Moore will address progress in clinical trials for stem cell based therapies.

About BioFlorida's 11th Annual Conference: The 2008 BioFlorida Annual Conference on October 19-21 at The Ritz-Carlton in Amelia Island brings together leading national speakers as the state's largest bioscience forum reaches key business and scientific leaders from all sectors of the industry. In its 11th year, this premier conference showcases Florida's bioscience technologies with sessions tailored to those involved in the business of medical device, biotechnology and pharmaceutical research. This year's pivotal conference focuses on product development stages with topics that include partnering, clinical trials and drug discovery.

The forum provides attendees with insight into how the industry is dealing with today's economic and political environment. Attendees gain knowledge from distinguished speakers that include Yank D. Coble Jr., MD from University of North Florida; James C. Greenwood from the Biotechnology Industry Organization; Bob Ingram from GlaxoSmithKline; Stephen N. Oesterle, MD from Medtronic; and Jacksonville Mayor John Peyton. "Florida is ranked as one of the top five regions worldwide for attracting biotechnology companies by Fierce Biotech," said Russell Allen, president of BioFlorida, "The outcomes and dialogue generated during this annual conference guide critical efforts to further improve the business climate for bioscience companies throughout Florida."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a Canadian public biotechnology company (TSX VENTURE:SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair neurological function lost due to disease or injury. SCT's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, ALS.

These securities have not been registered under the United States Securities Act of 1933, as amended, or the securities laws of any state, and may not be offered or sold within the United States or to, or for the account or benefit of U.S. persons unless an applicable exemption from U.S. registration requirements is available.

Except for historical information, this press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information